5th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference

7th - 8th March 2024

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

Leveraging next gen technologies beyond conventional biomarker drug discovery

The emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology, immuno-therapies, data interpretation and unconventional design of clinical trials.

Tag Line
20+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Challenges in NGS based CDx and the Importance of imaging biomarkers for precision medicine.
Tag Line
Opportunity to develop long-lasting business relationships and networking opportunities with senior peers. Get the Opportunity to get your queries handled by Biomarker experts in one on one session.
Tag Line
Facilitated networking sessions to ensure quality interactions along with Case studies from experts who have successfully created and developed a biomarker

The 5th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th - 8th March 2024 in London, UK would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding the commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers.

CO-LOCATED CONFERENCES

8th Annual MarketsandMarkets Next-Gen Immuno-Oncology Conference

WHAT TO EXPECT

  • Clinical biomarker identification and qualification 
  • Biomarkers and personalized medicine 
  • Assay development and validation
  • NGS and novel technologies in biomarker discovery
  • Commercialization of biomarkers in therapeutic and CDx applications

  • Researchers, scientists, clinicians, academicians and professionals From Pharmaceutical companies, Bio-pharma companies, Universities and Research Institutes.

Departments:

  • Biomarker discovery/development | Translational research | Clinical Biomarker | Biomarkers in IO and Neurological disorders

 

CONFERENCE AGENDA

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

BIOMARKER DRUG DISCOVERY AND ASSAY VALIDATION

Keynote Presentation - ICT01, an anti-BTN3A mAb activating Vg9Vd2 cells

Emmanuel Valentin

Emmanuel Valentin, Vice President, Translational Medicine, Imcheck Therapeutics

09:00 - 09:30

Biomarker assay development and validation for cancer treatment

Nathalie Steinhoff

Nathalie Steinhoff, Scientist, Cancer Immunotherapy, Numab Therapeutics AG

Valerie Balme

Valerie Balme, Associate Director, Business Development, Veracyte

09:30 - 10:00

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Transforming Oncology with Predicine’s Liquid Biopsy Solutions

Dr. Pan Du

Dr. Pan Du, Co-founder, president and CTO , Predicine

11:15 - 11:45

Combination Strategies for Personalised Cancer Therapy

Sreejith Raveendran

Sreejith Raveendran, Assistant Professor, Teesside University

11:45 - 12:15

Sample quality strategies, operations and patient centricity for biomarker analysis

Debora Souza Da Costa

Debora Souza Da Costa, Senior Biosample Project Leader., Roche

12:15 - 12:45

Comprehensive Biomarker Strategies To Decipher The Tumor Microenvironment: From Tissue To High-Quality Spatial Insights

Angela Vasaturo

Angela Vasaturo , Director of Scientific Affairs, Ultivue

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

ROLE OF BIOMARKERS IN PERSONALIZED MEDICINE

AI-driven analysis of morphological biomarkers for trials in haemato-oncology

Daniel Royston

Daniel Royston, Consultant Clinical Advisor, Ground Truth Labs

14:15 - 14:45

AI in medicine - A paradigm shift for the diagnostic industry

Thomas Gohl

Thomas Gohl, Market Development Manager, Roche Diagnostics

14:45 - 15:15

Development of a colorectal cancer methylation panel and an actionable cancer mutation panel using targeted bisulfite next-generation sequencing

Collin Hudzik

Collin Hudzik, Scientist in product and business development , EpigenDx

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Lifestyle and epigenetic changes

Aparna Duggirala

Aparna Duggirala, Lecturer, Clinical Genetics, University of Derby

16:30 - 17:00

Back translation of preclinical models to humans

Maria Dermit

Maria Dermit, Computational Biologist, Novo Nordisk

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 18:00

Drinks Reception & Networking ....End of Day 1....

18:00 - 18:00

Registration

08:15 - 08:50

Welcome note from MarketsandMarkets

08:50 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

FROM BIOMARKERS TO CDx: STRATEGIES TO ACCELERATE CDx DEVELOPMENT AND COMMERCIALIZATION

Keynote Presentation : Use of biomarkers in clinical development to guide dosing regimen recommendation with the use of modelling and simulations models.

Patrick Brossard

Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

09:00 - 09:30

Tracking challenging pharmacodynamic biomarkers in normal tissue on Phase I clinical trials of new oncology agents

Karen Swales

Karen Swales, Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research

09:30 - 10:00

With only 1/500 Biomarkers reaching the patient what can we do better?

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

CLINICAL APPLICATIONS OF BIOMARKERS IN IMMUNOLOGY, NEUROLOGY, AND OTHER DISEASES

Anti-CD89 antibody for personalized treatment of IgA-mediated inflammatory disorders: Autoantigen-specific IgA, a biomarker with strong effector functions.

Louis Boon

Louis Boon, CSO , JJP Biologics

11:15 - 11:45

The Lymphocyte Stability Index - a pan-cancer biomarker for response to immune checkpoint blockade

Robert Watson

Robert Watson, Clinical Lecturer, University of Oxford

11:45 - 12:15

Histone based liquid biopsies for the screening of cancer and cardiovascular diseases

Manlio Vinciguerra

Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool

12:15 - 12:45

Generating pseudo-time progression of mucosal inflammation during Inflammatory Bowel Disease using spatially resolved multi-omics data

Priyank Patel

Priyank Patel, Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Panel Discussion: What are the biggest challenges faced in developing an assay: why and what have we learnt from it ?

Patrick Brossard

Patrick Brossard, Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

Christopher Peters

Christopher Peters, Clinical Senior Lecturer, Imperial College London

Maria Dermit

Maria Dermit, Computational Biologist, Novo Nordisk

Manlio Vinciguerra

Manlio Vinciguerra, European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool

Fernando Oneissi Martinez Estrada

Fernando Oneissi Martinez Estrada, Senior Lecturer in Innate Immunology, University of Surrey

14:15 - 14:45

Closing Remarks from the Chairperson

14:45 - 14:50

END OF CONFERENCE

14:50 - 14:50

SPEAKERS

Debora Souza Da Costa

Debora Souza Da Costa

Senior Biosample Project Leader., Roche

Angela Vasaturo

Angela Vasaturo

Director of Scientific Affairs, Ultivue

Priyank Patel

Priyank Patel

Senior Scientist, Department of Immunology & Respiratory Discovery Research, Boehringer Ingelheim Pharmaceuticals, Inc

Nathalie Steinhoff

Nathalie Steinhoff

Scientist, Cancer Immunotherapy, Numab Therapeutics AG

Louis Boon

Louis Boon

CSO , JJP Biologics

Manlio Vinciguerra

Manlio Vinciguerra

European Research Area (ERA) Chair, Medical University Varna & Faculty, Liverpool John Moores University, Liverpool

Collin Hudzik

Collin Hudzik

Scientist in product and business development , EpigenDx

Daniel Royston

Daniel Royston

Consultant Clinical Advisor, Ground Truth Labs

Emmanuel Valentin

Emmanuel Valentin

Vice President, Translational Medicine, Imcheck Therapeutics

Patrick Brossard

Patrick Brossard

Director, Clinical Pharmacology, SOBI - Swedish Orphan Biovitrum AB

Robert Watson

Robert Watson

Clinical Lecturer, University of Oxford

Aparna Duggirala

Aparna Duggirala

Lecturer, Clinical Genetics, University of Derby

Christopher Peters

Christopher Peters

Clinical Senior Lecturer, Imperial College London

Sreejith Raveendran

Sreejith Raveendran

Assistant Professor, Teesside University

Maria Dermit

Maria Dermit

Computational Biologist, Novo Nordisk

Ian Pike

Ian Pike

Chief Scientific Officer, Proteome Sciences PLC

Thomas Gohl

Thomas Gohl

Market Development Manager, Roche Diagnostics

Karen Swales

Karen Swales

Senior Scientific Officer, Clinical PD Biomarker Group, The Institute of Cancer Research

Dr. Pan Du

Dr. Pan Du

Co-founder, president and CTO , Predicine

Valerie Balme

Valerie Balme

Associate Director, Business Development, Veracyte

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Park Plaza Victoria London by Radisson, 239 Vauxhall Bridge Rd, Pimlico, London SW1V 1EQ, UK

PAST EVENT GALLERY